Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record.

Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma

Quinn, Jennifer A., Pluda, James, Dolan, M. Eileen, Delaney, Shannon, Kaplan, Richard, Rich, Jeremy N., Friedman, Allan H., Reardon, David A., Sampson, John H., Colvin, O. Michael, Haglund, Michael M., Pegg, Anthony E., Moschel, Robert C., McLendon, Roger E., Provenzale, James M., Gururangan, Sridharan, Tourt-Uhlig, Sandra, Herndon, James E., Bigner, Darell D., Friedman, Henry S.·2002·Journal of Clinical Oncology

Abstract

PURPOSE: We conducted a phase II trial of carmustine (BCNU) plus the O 6-alkylguanine-DNA alkyltransferase inhibitor O 6-benzylguanine (O 6-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas. PATIENTS AND METHODS: Patients were treated with O 6-BG at an intravenous dose of 120 mg/m 2 followed 1 hour later by 40 mg/m 2 of BCNU, with cycles repeated at 6-week intervals. RESULTS: Eighteen patients were treated (15 with glioblastoma multiforme, two with anaplastic astrocytoma, and one with malignant glioma). None of the 18 patients demonstrated a partial or complete response. Two patients exhibited stable disease for 12 weeks before their tumors progressed. Three patients demonstrated stable disease for 6, 12, and 18 weeks before discontinuing therapy because of hematopoietic toxicity. Twelve patients experienced reversible ≥ grade 3 hematopoietic toxicity. There was no difference in half-lives (0.56 ± 0.21 hour v 0.54 ± 0.20 hour) or area under the curve values (4.8 ± 1.7 μg/mL/h v 5.0 ± 1.3 μg/mL/h) of O 6-BG for patients receiving phenytoin and those not treated with this drug. CONCLUSION: These results indicate that O 6-BG plus BCNU at the dose schedule used in this trial is unsuccessful in producing tumor regression in patients with nitrosourea-resistant malignant glioma, although stable disease was seen in five patients for 6, 12, 12, 12, and 18 weeks. Future use of this approach will require strategies to minimize dose-limiting toxicity of BCNU such as regional delivery or hematopoietic stem-cell protection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2002.09.084

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 189

Metadata

Authors
Quinn, J. A., Pluda, J., Dolan, M. E., Delaney, S., Kaplan, R., Rich, J. N., Friedman, A. H., Reardon, D. A., Sampson, J. H., Colvin, O. M., Haglund, M. M., Pegg, A. E., Moschel, R. C., McLendon, R. E., Provenzale, J. M., Gururangan, S., Tourt-Uhlig, S., Herndon, J. E., Bigner, D. D., & Friedman, H. S.
Venue
Journal of Clinical Oncology
Published
2002-05-01
Volume
20
Issue
9
Pages
2277-2283
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2103270230
Cited by
189
References
0
FWCI
7.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma. https://app.cochat.ai/papers/10.1200/jco.2002.09.084
The paper
Quinn, J. A., Pluda, J., Dolan, M. E., Delaney, S., Kaplan, R., Rich, J. N., Friedman, A. H., Reardon, D. A., Sampson, J. H., Colvin, O. M., Haglund, M. M., Pegg, A. E., Moschel, R. C., McLendon, R. E., Provenzale, J. M., Gururangan, S., Tourt-Uhlig, S., Herndon, J. E., Bigner, D. D., & Friedman, H. S. (2002). Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2002.09.084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.